Executive to join company on September 1.
After serving as CEO for Zimmer Biomet since 2017, Bryan Hanson has been appointed as the new CEO of 3M’s Health Care Business Group. Expected to take the reins when the independent health care company is spun off from 3M, Hanson will officially join the organization on September 1.
As a separate entity, 3M believes that Health Care Business Group will be better positioned to deliver industry-leading innovation that enables better, smarter, and safer healthcare for patients worldwide.
“We are pleased to have Bryan join us to advance the spin-off of our Health Care business and build a leading independent medical technology innovation company,” said Mike Roman, 3M chairman, CEO. “His industry expertise, ability to drive growth, and track record of building a strong culture and teams will make an immediate impact.”
Reference: Bryan Hanson Named CEO of 3M’s Health Care Business Group. 3M. August 22, 2023. Accessed August 23, 2023. https://news.3m.com/Bryan-Hanson-Named-CEO-of-3Ms-Health-Care-Business-Group
Beyond the Birthrate: The Societal Costs of Maternal Mortality
September 6th 2024Head of Medical Affairs and Outcomes Research at Organon, Charlotte Owens, MD, FACOG, discusses the most critical changes needed to close the gaps in R&D for maternal health solutions and how feasible they are to make.
Efsitora Demonstrates Non-Inferiority vs. Insulin Glargine, Degludec for Type 2 Diabetes
September 5th 2024Results from the QWINT-1 and QWINT-3 trials found that insulin-naïve patients achieved similar reductions in A1C levels using once-weekly efsitora compared to daily insulin glargine and degludec.